US EditionFDA Approves Updated Label for Miach Orthopaedics’ BEAR® Implant to Include Significantly Lower Risk of Osteoarthritis
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
FDA Approves Updated Label for Miach Orthopaedics’ BEAR® Implant to Include Significantly Lower Risk of Osteoarthritis
6x Higher Rate of Post-Traumatic Osteoarthritis (PTOA) for ACL Reconstruction Compared to BEAR Implant Observed in BEAR I and II Studies WESTBOROUGH, Mass.–(BUSINESS WIRE)–#ACLrepair—Miach Orthopaedics, Inc., a company transforming the treatment of anterior cruciate ligament (ACL) tears, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for updated labeling of the BEAR® (Bridge-Enhanced ACL Restoration) Impl…
FDA Approves Updated Label for Miach Orthopaedics’ BEAR® Implant to Include Significantly Lower Risk of Osteoarthritis – Ortho Spine News
6x Higher Rate of Post-Traumatic Osteoarthritis (PTOA) for ACL Reconstruction Compared to BEAR Implant Observed in BEAR I and II Studies WESTBOROUGH, Mass., January 14, 2026 -(BUSINESS WIRE)- Miach Orthopaedics, Inc., a company transforming the treatment of anterior cruciate ligament (ACL) tears, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for updated labeling of the BEAR® (Bridge-Enhanced ACL Restorati
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
